Healthcare / BiotechnologyASX
$0.05
-0.00 (-2.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-5.9M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-64.6%
↓Gross Margin
65.4%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+112.0%
FCF CAGR
—
FCF margin
-84.2%
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.3M · net income $-5.2M · FCF $-6.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.3M | $7.3M | $4.9M | $1.8M | $765193.00 |
| Net Income | $-5.2M | $-5.2M | $-6.9M | $-3.8M | $-2.9M |
| EBITDA | $-5.2M | $-5.2M | $-6.9M | $-3.7M | $-2.8M |
| EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.01 |
| Gross Margin | 65.4% | 65.4% | 68.1% | 72.5% | 68.4% |
| Operating Margin | -73.5% | -73.5% | -106.4% | -188.8% | -407.4% |
| Net Margin | -71.6% | -71.6% | -141.5% | -209.8% | -373.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 8.04 | 8.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.1M | $-6.1M | $-5.9M | $-2.6M | $-3.2M |
| Returns | |||||
| ROE | -64.6% | -64.6% | -54.6% | -19.3% | -12.3% |
| Valuation | |||||
| P/B | 1.32 | 1.32 | 1.58 | 0.90 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | 48.6% | 48.6% | 171.7% | 135.8% | — |
| EPS Growth | 25.3% | 25.3% | -83.1% | -32.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.02
Residual
-31.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.